Search
Biofrontera Inc
BFRIAdd to Watchlist
0.800USD
-0.189-19.08%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
10.24MMarket Cap
LossP/E TTM
More Details of Biofrontera Inc Company
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
Biofrontera Inc Info
Ticker SymbolBFRI
Company nameBiofrontera Inc
IPO dateOct 14, 2021
CEOLuebbert (Hermann)
Number of employees92
Security typeOrdinary Share
Fiscal year-endOct 14
Address120 Presidential Way,
CityWOBURN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01801
Phone17812451325
Websitehttps://www.biofrontera-us.com/
Ticker SymbolBFRI
IPO dateOct 14, 2021
CEOLuebbert (Hermann)
Company Executives of Biofrontera Inc
Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
290.21K
+47.38%
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
175.00K
+50.00%
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Mr. George Jones
Mr. George Jones
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
290.21K
+47.38%
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
175.00K
+50.00%
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Revenue Breakdown
FY2025
FY2024
FY2023
FY2022
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
41.70M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rosalind Advisors, Inc.
9.50%
AIGH Capital Management, LLC.
5.80%
Hewlett Fund, L.P.
3.93%
Biofrontera AG
3.33%
Lytton (Laurence W)
2.55%
Other
74.88%
Shareholders
Shareholders
Proportion
Rosalind Advisors, Inc.
9.50%
AIGH Capital Management, LLC.
5.80%
Hewlett Fund, L.P.
3.93%
Biofrontera AG
3.33%
Lytton (Laurence W)
2.55%
Other
74.88%
Shareholder Types
Shareholders
Proportion
Hedge Fund
12.10%
Corporation
7.26%
Individual Investor
6.43%
Private Equity
6.29%
Investment Advisor/Hedge Fund
2.37%
Investment Advisor
1.71%
Research Firm
0.28%
Venture Capital
0.16%
Other
63.40%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
37
2.75M
22.90%
-276.67K
2025Q4
34
2.85M
28.39%
--
2025Q3
35
2.85M
24.13%
+509.58K
2025Q2
38
2.48M
28.99%
+6.08K
2025Q1
43
1.91M
35.97%
-1.28M
2024Q4
42
2.24M
20.22%
+365.98K
2024Q3
37
1.95M
35.26%
+44.70K
2024Q2
40
1.95M
40.02%
-47.81K
2024Q1
39
1.85M
15.80%
+1.04M
2023Q4
36
279.45K
16.52%
+54.33K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rosalind Advisors, Inc.
1.14M
9.79%
--
--
Dec 31, 2025
AIGH Capital Management, LLC.
696.57K
5.98%
-102.15K
-12.79%
Dec 31, 2025
Hewlett Fund, L.P.
472.22K
4.05%
-78.00K
-14.18%
Dec 03, 2025
Biofrontera AG
400.00K
3.43%
--
--
Sep 16, 2025
Lytton (Laurence W)
306.70K
2.63%
-228.98K
-42.75%
Mar 31, 2025
Armistice Capital LLC
291.15K
2.5%
+141.15K
+94.10%
Sep 30, 2024
Luebbert (Hermann)
290.21K
2.49%
+137.50K
+90.04%
Mar 05, 2026
Worth Venture Partners, LLC
218.64K
1.88%
-28.69K
-11.60%
Dec 31, 2025
Leffler (Eugene Frederick)
175.00K
1.5%
+87.50K
+100.00%
Mar 05, 2026
Geode Capital Management, L.L.C.
65.68K
0.56%
+23.07K
+54.16%
Dec 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
